Want to see TSE:OPTI full AI Analyst Report?
Top Page
Optimi Health
(OPTI)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$5.50
▲(1618.75% Upside)
Action:Reiterated
Date:06/19/26
The score is primarily weighed down by weak financial performance (ongoing losses, negative gross profit, persistent cash burn, and higher leverage). Technicals also remain soft with the stock trading below major moving averages and a negative MACD. Valuation offers limited support because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Revenue Growth
Sustained top-line growth demonstrates expanding commercial traction in regulated psychedelic supply and services. Over a 2-6 month horizon, growing revenue provides a larger base to absorb fixed costs and supports scale economies, which can enable margin recovery if cost structure is managed.
Negative Factors
Negative unit economics
Negative gross profit indicates core product/service pricing or cost issues that undermine sustainable profitability. Without improved unit economics, revenue growth alone can increase cash burn; durable recovery requires either higher margins or structural cost reductions to reach positive operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line growth demonstrates expanding commercial traction in regulated psychedelic supply and services. Over a 2-6 month horizon, growing revenue provides a larger base to absorb fixed costs and supports scale economies, which can enable margin recovery if cost structure is managed.
Read all positive factors
Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$41.63M
Dividend YieldN/A
Average Volume (3M)169.72K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees9
SectorHealthcare
Sector Strength45
IndustryAgricultural Farm Products
Share Statistics
EPS (TTM)-1.68
Shares Outstanding5,625,899
10 Day Avg. Volume137,724
30 Day Avg. Volume169,715
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.70
Price to Sales (P/S)87.81
P/FCF Ratio-13.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Optimi Health Business Overview & Revenue Model
Company Description
Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and ...
How the Company Makes Money
Optimi Health’s revenue model is based on commercializing regulated psychedelic-related manufacturing and services where permitted by law. Key revenue streams include: (1) Product sales/supply of regulated psychedelic substances and APIs to author...
Optimi Health Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
32
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 231.86K | 426.30K | 389.85K | 181.09K | 80.72K | 0.00 |
| Gross Profit | -3.07M | -2.07M | 270.91K | -157.04K | 53.92K | -47.12K |
| EBITDA | -3.59M | -2.23M | -4.74M | -4.42M | -7.03M | -5.95M |
| Net Income | -5.40M | -3.71M | -6.04M | -5.19M | -7.38M | -6.04M |
Balance Sheet | ||||||
| Total Assets | 13.51M | 15.21M | 14.55M | 16.49M | 16.82M | 23.46M |
| Cash, Cash Equivalents and Short-Term Investments | 106.71K | 1.15M | 103.66K | 1.34M | 1.89M | 12.43M |
| Total Debt | 6.57M | 6.68M | 2.75M | 1.71M | 157.58K | 250.84K |
| Total Liabilities | 9.97M | 8.64M | 4.98M | 3.28M | 797.66K | 2.40M |
| Stockholders Equity | 3.54M | 6.57M | 9.58M | 13.21M | 16.02M | 21.07M |
Cash Flow | ||||||
| Free Cash Flow | -3.29M | -2.72M | -4.43M | -4.41M | -11.73M | -10.96M |
| Operating Cash Flow | -3.21M | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M |
| Investing Cash Flow | -88.41K | -88.38K | -154.02K | -706.02K | -3.15M | -9.19M |
| Financing Cash Flow | 3.35M | 3.76M | 3.19M | 3.76M | 1.19M | 19.18M |
Optimi Health Technical Analysis
Positive
0.32
Price Trends
8.29
Negative
8.75
Negative
9.37
Negative
Market Momentum
-0.48
Negative
53.38
Neutral
38.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Positive. The current price of 0.32 is below the 20-day moving average (MA) of 6.56, below the 50-day MA of 8.29, and below the 200-day MA of 9.37, indicating a neutral trend. The MACD of -0.48 indicates Negative momentum. The RSI at 53.38 is Neutral, neither overbought nor oversold. The STOCH value of 38.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OPTI.
Optimi Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | C$29.74M | -3.38 | -19.10% | ― | 0.66% | -14.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$11.52M | -2.59 | ― | ― | -25.05% | 67.74% | |
46 Neutral | C$31.57M | -24.86 | 7.78% | ― | 16.45% | -6.36% | |
45 Neutral | C$13.85M | -2.64 | 75.85% | ― | 33.00% | 40.74% | |
41 Neutral | C$41.63M | -4.24 | -94.46% | ― | ― | ― | |
41 Neutral | C$15.72M | -4.08 | -68.32% | ― | 1.96% | -24.60% |
* Healthcare Sector Average
TSE:OPTI
Optimi Health
7.40
2.30
45.10%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.10
-47.50%
TSE:LABS
MediPharm Labs
0.07
0.00
0.00%
TSE:PCLO
PharmaCielo
0.07
0.02
30.00%
TSE:ROMJ
Rubicon Organics
0.47
0.03
8.05%
TSE:AVCN
Avicanna
0.13
-0.15
-54.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.